VP2 Stock Overview
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Valeo Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.04 |
| 52 Week High | CA$0.32 |
| 52 Week Low | CA$0.033 |
| Beta | 2.53 |
| 1 Month Change | -62.02% |
| 3 Month Change | -80.45% |
| 1 Year Change | -87.50% |
| 3 Year Change | -94.87% |
| 5 Year Change | n/a |
| Change since IPO | -94.69% |
Recent News & Updates
Recent updates
Shareholder Returns
| VP2 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -30.1% | 1.9% | 1.2% |
| 1Y | -87.5% | -28.2% | 2.0% |
Return vs Industry: VP2 underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: VP2 underperformed the German Market which returned 2% over the past year.
Price Volatility
| VP2 volatility | |
|---|---|
| VP2 Average Weekly Movement | 42.8% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: VP2's share price has been volatile over the past 3 months.
Volatility Over Time: VP2's weekly volatility has increased from 31% to 43% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 100 | Steve Saviuk | www.valeopharma.com |
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson’s disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. It also offers Hesperco, a flavonoid formulation used for immune support; Ethacrynate Sodium; and Amikacin, an antibiotic.
Valeo Pharma Inc. Fundamentals Summary
| VP2 fundamental statistics | |
|---|---|
| Market cap | €7.76m |
| Earnings (TTM) | -€19.43m |
| Revenue (TTM) | €37.10m |
0.2x
P/S Ratio-0.4x
P/E RatioIs VP2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VP2 income statement (TTM) | |
|---|---|
| Revenue | CA$54.29m |
| Cost of Revenue | CA$40.84m |
| Gross Profit | CA$13.44m |
| Other Expenses | CA$41.88m |
| Earnings | -CA$28.43m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.29 |
| Gross Margin | 24.76% |
| Net Profit Margin | -52.37% |
| Debt/Equity Ratio | -138.2% |
How did VP2 perform over the long term?
See historical performance and comparison